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Abstract: Trace Amine-Associated Receptor 1 (TAAR1) is a potential target for the treatment of
depression and other CNS disorders. However, the precise functional roles of TAAR1 to the actions
of clinically used antidepressants remains unclear. Herein, we addressed these issues employing
the TAAR1 agonist, o-phenyl-iodotyramine (o-PIT), together with TAAR1-knockout (KO) mice.
Irrespective of genotype, systemic administration of o-PIT led to a similar increase in mouse brain
concentrations. Consistent with the observation of a high density of TAAR1 in the medial preoptic
area, o-PIT-induced hypothermia was significantly reduced in TAAR1-KO mice. Furthermore, the
inhibition of a prepulse inhibition response by o-PIT, as well as its induction of striatal tyrosine
hydroxylase phosphorylation and elevation of extracellular DA in prefrontal cortex, were all reduced
in TAAR1-KO compared to wildtype mice. O-PIT was active in both forced-swim and marble-
burying tests, and its effects were significantly blunted in TAAR1-KO mice. Conversely, the actions
on behaviour and prefrontal cortex dialysis of a broad suite of clinically used antidepressants were
unaffected in TAAR1-KO mice. In conclusion, o-PIT is a useful tool for exploring the hypothermic
and other functional antidepressant roles of TAAR1. By contrast, clinically used antidepressants do
not require TAAR1 for expression of their antidepressant properties.
Keywords: TAAR1; o-PIT; DA; antidepressants
1. Introduction
Trace amines (TAs) are a diverse group of aminergic compounds that, in mammals,
are either derived from the intake of food such as cheese, from the metabolism of thyroid
hormone or from enzymatic pathways of synthesis in nervous tissue [1,2]. Enzymatic
decarboxylation of the aromatic amino acids phenylalanine, tyrosine and tryptophan [3]
respectively yields phenethylamine (PEA), tyramine and tryptamine [3]. In contrast to
classical monoamines, such as noradrenaline (NA) and serotonin (5-HT), these and other
TAs are present in far lower concentrations in brain and peripheral tissues [1,3]. TAs
nonetheless appear to be functionally important in the control of mood, energetic status,
cognition and other functions. Furthermore, it has been hypothesized that a disruption
of their activity may contribute to the pathophysiology of multiple classes of metabolic,
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neuropsychiatric and even neurodegenerative disorders, in particular major depression
and schizophrenia [1,3–6].
TAs have historically been considered “false transmitters”, since they displace
monoamines from intraneuronal vesicles and encourage their reverse transport, actions
thought to underlie sympathomimetic properties [7]. However, the notion that trace amines
exert neuromodulatory effects, themselves, via specific classes of receptors [8] was con-
cretized with the discovery of receptors that bind TAs in rodents [9,10], followed by the
identification of a whole family of G protein-coupled “Trace Amine-Associated Receptors”
(TAAR), now referred to as “TA” receptors [11]. Most classes of TAAR are highly expressed
in the olfactory epithelium and act as volatile TA detectors [12,13]. Conversely, TAAR1 is
mainly found in organs of the alimentary system and the brain [14]. In particular, TAAR1 is
expressed in monoaminergic cell groups such as cortical and striatal projecting dopamine
(DA) neurons, as well as corticolimbic projecting 5-HT neurons. Moreover, TAAR1 is found
in the prefrontal cortex, entorhinal cortex, bed nucleus of stria terminalis, amygdala, hy-
pothalamus and lateral parabrachial nucleus [14–16]. TAAR1 is coupled to Gs and G13 and
responds to conventional, endogenous trace amines and amphetamine, methamphetamine
and MDMA [10,17–19]. Due to its distinctive relationship with DA releasing agents, much
TAAR1-related research has focused on the DAergic system. Mice lacking TAAR1 dis-
play higher VTA neuron firing rates [15,20,21] and heightened behavioural sensitivity to
psychostimulants [15,16,18,22], suggesting that pharmacological TAAR1 activation might
be beneficial for tackling schizophrenia. Indeed, TAAR1 agonists exhibit antipsychotic-
like activity in certain animal models [23,24]. There is also evidence for deficits in trace
amine activity in depression, and it has been reported that TAAR1 agonists improve affect,
displaying antidepressant properties in rodents and nonhuman primates [23].
In view of their therapeutic promise, extensive efforts have been made to develop
novel ligands for TAAR1 sites [25]. For example, the dual TAAR1/5-HT1A receptor agonist
SEP-363856 showed antipsychotic properties in schizophrenic patients [26]. Even though
larger trials are needed, SEP-363856 could become the first non-DA D2 receptor antago-
nist in clinical usage to exert antipsychotic efficacy [26]. Moreover, SEP-363856 displays
negligible antipsychotic-related side effects such as weight gain, prolactin increase and
occurrence of extrapyramidal symptoms [27]. In parallel with other TAAR1 agonists, pre-
clinical studies have shown that SEP-363856 displays antidepressant actions in rodents [24],
and beneficial effects of SEP-363856 in depressed patients may be revealed by future clinical
trials. Consistent with this possibility, several studies have shown that trace amines exert a
positive influence on affect, and that a reduction in their levels may be related to depressed
states in patients [16,28,29]. Furthermore, it has been conjectured that a component of
the antidepressant actions of Monoamine Oxidase inhibitors reflects their protection of
trace amines from degradation [16,28,30]. That is, their antidepressant properties might at
least partially depend upon increases in levels of trace amines and ipso facto activation of
TAAR1 receptors—or another subclass of TAAR [31]. Alternatively, TAAR1 may act as a
negative feedback regulator of trace amine levels, and TAAR1 antagonists might facilitate
the antidepressant actions of monoamine oxidase inhibitor [16]. This remains, however,
to be directly examined, and the putative role of TAAR1 in the actions of other classes of
antidepressant agent has not as yet been evaluated [14,25].
Apart from conventional TAs, there is another TA group called thyronamines that
display TAAR1 agonist properties. Unlike classical TAs, thyronamines are generated by
enzymatic decarboxylation of thyroid hormones with ornithine decarboxylase [32,33]. In
contrast to thyroid hormones, thyronamines reduce core temperature and cardiac out-
put [34,35]. Further, TAAR1 was suggested to mediate these actions [35], and there is
growing evidence for a close thyronamine-TAAR1 relationship [35–37]. Supporting this
hypothesis, it was shown that 3-iodothyronamine (T1AM) increases striatal DA synthesis
through TAAR1 signalling [38]. However, further research is needed to elucidate the precise
role of TAAR1 in the actions of thyronamines. One synthetic derivative of the thyronamine
family with high potency and selectivity for TAAR1 is o-phenyl-iodo-tyramine (o-PIT) [39].
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Hence, o-PIT may be a useful tool for investigation of the TAAR1-mediated actions of
thyronamines.
In view of the above observations, we exploited a neuroanatomical, neurochemical
and behavioural approach to characterize the actions of o-Pit in TAAR1-KO mice. We
particularly focused on readouts relevant to the influence of TAAR1 on DAergic neuro-
transmission and their potential role in the response to antidepressants. The data reveal a
significant contribution of TAAR1 to several functional properties of o-PIT, including its
actions in two “classic” antidepressant-responsive models, forced swimming and marble
burying in mice. We also exploited these procedures to examine in complementary experi-
ments whether TAAR1 sites are required for expression of the antidepressant actions of
clinically employed monoaminergic agents.
2. Results
2.1. Exposure to O-PIT and Histoenzymological Detection of β-Galactosidase in TAAR1-KO Mice
The TAAR1-KO mice used in the present study, lack the coding sequence of TAA1
which is replaced by the LacZ reporter gene (Figure 1A). Brain and plasma levels of
(exogenous) o-PIT were measured 60 min after intraperitoneal administration
(Figure 1B–C). Considerable amounts of o-PIT were detected in the brain in a dose-
dependent manner (2.5–40 mg/kg). Brain levels of o-PIT did not significantly differ
between WT and TAAR1-KO mice (Figure 1B). ANOVA indicated a nonsignificant GEN ×
DRUG interaction (F2, 18 = 0.7, NS) but a significant effect of DRUG (F2, 18 = 144.4, p < 0.01).
Plasma levels of o-PIT were likewise not influenced by the genotype, and a nonsignificant
GEN × DRUG interaction (F2, 17 = 2.8, NS) but a significant effect of DRUG (F2, 17 = 55.4,
p < 0.01) were also found (Figure 1C). In TAAR1-KO mice, X-gal deposits were detected in
medial preoptic nucleus (MPO), medial division of bed nucleus of stria terminalis (BSTM),
zona incerta and lateral hypothalamic area (ZI/LHA), basomedial and medial amygdaloid
nucleus (BMA/MeA), ventral tegmental area (VTA) and substantia nigra pars compacta
(SNC), layer 2 of lateral entorhinal cortex (LEnt), periaqueductal grey (PAG) and deep
layers of superior colliculus (DpSC) and dorsal part of lateral parabrachial nucleus (LPBD)
(Figure 1D). Our study did not include regions that lay caudal to pons.
2.2. Influence of O-PIT on Core Temperature in TAAR1-KO
It has been described that systemic administration of thyronamines reduces core body
temperature in rodents (Figure 2A) [40]. Basal core temperatures were 37.9 ± 0.1 ◦C
and 38.0 ± 0.1 ◦C in WT and TAAR1-KO mice, respectively, and were not statistically
different between genotypes. Administration of o-PIT dose-dependently decreased core
temperature in WT and TAAR1-KO mice, but its action was less marked in TAAR1-KO mice
(maximal fall to 34.8 ± 0.2 ◦C vs. 33.2 ± 0.6 ◦C in WT mice) (Figure 2B). ANOVA indicated
a significant GEN × DRUG interaction (F3, 54 = 2.8, p < 0.05), effect of DRUG (F3, 54 = 78.0,
p < 0.01) and effect of GEN (F1, 54 = 12.3, p < 0.01). Moreover, the influence of different classes
of monoaminergic antagonists upon the hypothermia induced by o-PIT (20 mg/kg, i.p.)
was evaluated (Figure 2C). Pretreatment with the α2-adrenoceptors antagonist, RX821,002,
which was inactive by itself (GEN × PRET interaction: F5, 89 = 0.6, NS), dose-dependently
attenuated the o-PIT-induced hypothermia both in WT and TAAR1-KO mice. The ability
of RX821,002 to reverse the effect of o-PIT was comparable between genotype as signed by
a nonsignificant GEN × PRET × DRUG interaction (F4, 154 = 1.1, NS).
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Figure 1. O-PIT brain and plasma pharmacokinetics in TAAR1-KO mice and TAAR1 distribution in the brain. (A) Chemical
structure of o-PIT and schematic representation of the TAAR1-KO mouse genetic construct. (B–C) Levels of o-PIT were
quantified in brain (B) and plasma (C) 60 min after administration. Levels are expressed as absolute values per weight
of brain sample (µg/mg) and volume of plasma (ng/mL). All data are means ± SEM. N = 4–5 per group. p < 0.05,
influence of treatment (#) or genotype (*). VEH: vehicle. (D) Neuroanatomical distribution of TAAR1 expressing cells using
β-galactosidase detection in TAAR1-KO mice sections and that the staining represents expression under the endogenous
TAAR1 promoter (N = 3). MPO: medial preoptic nucleus (scale bar: 100 µm), BSTM: medial bed nucleus of stria terminalis
(scale bar: 100 µm), ZI/LHA: zona incerta/lateral hypothalamic area (scale bar: 100 µm), BM/Me: basomedial/medial
amygdaloid nucleus (scale bar: 250 µm), VTA/SNC: ventral tegmental area/compact part of substantia nigra (scale bar:
250 µm), LEnt: lateral entorhinal cortex (scale bar: 250 µm), PAG/DpG/DpWh: periaqueductal grey/deep grey layer of
superior colliculus/deep white layer of superior colliculus (scale bar: 250 µm), LPBD: dorsal part of lateral parabrachial
nucleus (scale bar: 100 µm), 3V: 3rd ventricle, sm: stria medullaris, f: fornix, mfb: medial forebrain bundle, cp: cerebral
peduncle, ec: external capsule, scp: superior cerebellar peduncle, ml: medial lemniscus, Aq: aqueduct.
Int. J. Mol. Sci. 2021, 22, 8907 5 of 19
Figure 2. Drug interaction with o-PIT upon core temperature in TAAR1-KO and WT mice. (A) Schematic depiction of
hypothermic effects of o-PIT. (B) Core temperature is expressed as area under the curve (AUC) calculated over the 120 min
following administration of o-PIT (2.5–40 mg/kg). (C) Antagonists (mg/kg, s.c.) were administered 30 min prior to o-PIT
(20 mg/kg). Core temperature was determined 60 min following o-PIT. (C) Dose-dependent (0.01–0.63 mg/kg) effect of
RX821, 002 upon the effect of o-PIT. All data are means ± SEM. N = 6–8 per group. p < 0.05, influence of treatment (#) or
genotype (*). VEH: vehicle.
2.3. Influence of O-PIT on Prepulse Inhibition in TAAR1-KO Mice
O-PIT significantly increased the percent of prepulse inhibition (Figure 3A) in WT
mice but was inactive in TAAR1-KO mice, as indicated by a significant GEN × DRUG
interaction (F1, 44 = 5.1, p < 0.05; Figure 3B). The effect of o-PIT was independent of prepulse
intensity (GEN × DRUG × INTENSITY interaction (F3, 132 = 1.0, NS)). O-PIT had no effect
on the basal startle response in either genotype (drug effect: F1, 44 = 1.2, NS; GEN × DRUG
interaction: F1, 44 = 1.0, NS; Figure 3C).
Figure 3. Influence of o-PIT on prepulse inhibition in TAAR1-KO and WT mice. (A) Schematic
depiction of prepulse inhibition experiment. (B,C) Show that the enhancement by o-PIT of prepulse
inhibition (B) is specific in that it does not affect the startle reflex, per se, neither in WT nor in
TAAR1-KO mice (C). Data represent means ± SEM. N = 8–12 per group. p < 0.05, influence of
treatment (#) or genotype (*). VEH: vehicle.
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2.4. Induction by O-PIT of Tyrosine Hydroxylase Phosphorylation (TH) and Activity in the
Caudoputamen (CPu)
To investigate the role of o-PIT–TAAR1 interaction in DAergic system, o-PIT was
applied in CPu coronal slices, which were subsequently used for WB analysis (Figure 4A).
O-PIT concentration dependently enhanced the Ser19 phosphorylation of TH in the CPu
of WT but not TAAR1-KO mice (GEN effect: F3, 40 = 3.052, p < 0.05; Figure 4B–C). Similar
trends, although not significant, were found on Ser31 and Ser40 in WT and TAAR1-KO
mice (Ser31 GEN effect: F3, 39 = 3.39, NS; Ser40 GEN effect: F3, 40 = 1.25, NS; Figure 4D–E). In
all cases, the effects were biphasic, with a further increase in concentrations leading to an
inversion of the concentration–response curve.
Figure 4. Influence of o-PIT on Tyrosine Hydroxylase (TH) phosphorylation in CPu of TAAR1-KO and WT mice.
(A) Schematic depiction of experimental procedure. (B) Immunoblots of P-Ser19-TH, P-Ser31-TH, P-Ser40-TH and total-TH
were quantified following increasing concentrations of o-PIT (1–100 µM). (C–E) Bar graphs showing the immunoblot
quantification of P-Ser19-TH (C), P-Ser31-TH (D), P-Ser40-TH (E). CPu TH activity was measured following the perfusion of
10 µM o-PIT. Data are expressed as percentage of vehicle (100%). All data are means ± SEM. N = 4–5 per group. p < 0.05,
influence of treatment (#) or genotype (*). VEH: vehicle.
2.5. Influence of O-PIT upon Dialysis Levels of DA, NA and 5-HT in the mPFC of Freely Moving
TAAR1-KO Mice
A microdialysis probe was implanted in mPFC, which contains DA, 5-HT, nora-
drenaline (NA) and acetylcholine afferents (Figure 5A). No change in basal extracellu-
lar levels of DA, 5-HT or NA was detected in the frontal cortex of TAAR1-KO mice
(Table 1). Injection of 10 mg/kg o-PIT elicited a sustained elevation in DA levels in WT
Int. J. Mol. Sci. 2021, 22, 8907 7 of 19
but not TAAR1-KO mice, as indicated by a significant TIME × GEN × DRUG interaction
(F18, 168 = 2.6, p < 0.01; Figure 5B). Subsequent analyses indicated that o-PIT was active in
WT mice (TIME × DRUG interaction: F8, 96 = 3.5, p < 0.01) but was inactive in TAAR1-KO
mice (F8, 72 = 1.9, NS). However, at the dose of 20 mg/kg, o-PIT elicited a significant increase
in DA levels in TAAR1-KO mice (AUC; Figure 5C), suggesting that the effect of o-PIT was
blunted in TAAR1-KO mice (GEN × DRUG interaction: F3, 40 = 2.67, p < 0.05). Underlining
a specific action of o-PIT upon DAergic transmission, levels of 5-HT and NA, detected
concomitantly, were not altered by 10 mg/kg o-PIT (Figure 5D–E). Likewise, o-PIT was
without effect upon acetylcholine and amino acids levels (Table 1). Finally, evaluated upon
subcortical monoaminergic transmission, the effect of 10 mg/kg o-PIT was comparable
between WT and TAAR1-KO mice (Table 1).
Figure 5. Effect of o-PIT (10 mg/kg) on extracellular levels of DA, 5-HT and NA in the mPFC of
TAAR1-KO and WT mice. (A) Schematic depiction of experimental procedure. (B) The vertical dotted
line indicates the time at which o-PIT (10 mg/kg) was administered. DA levels are expressed as a
percentage of baseline (100%). (C–E) Histograms show values of area under the curve (AUC [0..180],
arbitrary units) for the dose–response of o-PIT upon DA (C) and for the effect of 10 mg/kg o-PIT on
NA (D) and 5-HT (E). All data are means ± SEM. N = 6–8 per group. p < 0.05, influence of treatment
(#) or genotype (*). VEH: vehicle.
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Table 1. Resting levels and o-PIT-induced changes in biogenic amines, acetylcholine and amino acids in dialysates of mPFC
in freely moving mice. Values are mean ± SEM concentration not corrected for probe recovery. N ≥ 8 per groups. * p < 0.05
WT vs. TAAR1-KO.
Resting Levels o-PIT (10 mg/kg i.p.) [AUC; % of Vehicle]
(Units) WT TAAR1-KO WT TAAR1-KO
DA (pM) 238.87 ± 30.13 203.49 ± 23.84 160 ± 13 109 ± 6 *
NA (pM) 445.49 ± 25.79 411.87 ± 22.47 115 ± 5 106 ± 4
5-HT (pM) 188.29 ± 15.19 209.08 ± 22.40 109 ± 8 102 ± 4
Acetylcholine (nM) 0.92 ± 0.10 1.13 ± 0.14 98 ± 7 107 ± 20
Alanine (µM) 0.90 ± 0.12 1.18 ± 0.21 94 ± 3 84 ± 4
Arginine (µM) 0.38 ± 0.07 0.48 ± 0.10 89 ± 2 91 ± 4
Aspartate (µM) 70.83 ± 20.45 69.98 ± 20.50 103 ± 5 105 ± 6
GABA (µM) 10.74 ± 1.82 13.24 ± 3.19 87 ± 8 82 ± 8
Glutamate (µM) 2.05 ± 0.71 1.64 ± 0.83 106 ± 3 101 ± 3
Glutamine (µM) 9.55 ± 2.26 13.61 ± 3.73 106 ± 5 101 ± 5
Glycine (µM) 1.08 ± 0.10 1.53 ± 0.29 93 ± 2 90 ± 2
Phenethylamine (µM) 0.40 ± 0.08 0.32 ± 0.09 108 ± 3 114 ± 6
L-serine (µM) 1.31 ± 0.18 1.58 ± 0.25 96 ± 2 96 ± 5
D-serine (µM) 0.45 ± 0.09 0.35 ± 0.06 95 ± 4 107 ± 4
Taurine (µM) 6.92 ± 1.64 6.99 ± 3.20 116 ± 6 105 ± 4
2.6. Influence of Classical Antidepressants upon Dialysis Levels of DA, NA and 5-HT in the mPFC
of Freely Moving TAAR1-KO Mice
WT and TAAR1-KO mice were injected with 10 mg/kg of Venlafaxine, Citalopram,
Bupropion, Selegiline or Reboxetine, and levels of monoamines were measured by mi-
crodialysis in mPFC (Figure 6A). DA, NA and 5-HT were significantly affected by an-
tidepressant DRUG treatment (DRUG effect: F5, 63 = 34.9, p < 0.01; F5, 66 = 34.96, p < 0.01;
F5, 65 = 27.15, p < 0.01, respectively; Figure 6B–D). However, DA, NA and 5-HT did not
display any significant genotype effect (GEN effect: F1, 63 = 2.8, NS; F1, 66 = 0.99, NS;
F1, 65 = 0.52, NS, respectively; Figure 6B–D). Post hoc analysis revealed that Venlafaxine and
Citalopram increased 5-HT levels, Selegiline increased DA and NA levels and Reboxetine
increased NA and 5-HT levels (Figure 6B–D). These effects were observed in both WT and
TAAR1-KO mice (Figure 6B–D).
2.7. Influence of O-PIT and Commonly Used Antidepressants on the Forced-Swim Test in
TAAR1-KO Mice
In the forced-swim test (Figure 7A), TAAR1-KO mice showed a spontaneous but not
reproducible decrease in total time of immobility, which was 210.0 ± 10.0 sec in WT mice
and 154.6 ± 21.7 sec in TAAR1-KO mice (F1, 15 = 6.7, p < 0.01; Figure 7B). The effect of
o-PIT was influenced by the genotype, as indicated by the significant GEN × DRUG interac-
tion (F3, 51 = 2.9, p < 0.05). The time of immobility was dose-dependently (2.5–40 mg/kg)
reduced by o-PIT in WT mice (F3, 29 = 5.8, p < 0.01) but was absent in TAAR1-KO mice
(F3, 22 = 0.5, NS). In contrast, TAAR1-KO mice displayed similar reduction of immobility
time compared to the WT mice after the administration of duloxetine, venlafaxine, maproti-
line, fluoxetine, bupropion, radafaxine, selegiline and reboxetine (GEN × DRUG interaction:
F3, 40 = 1.2, NS; F3, 79 = 0.3, NS; F4, 54 = 0.8, NS; F3, 46 = 1.4, NS; F4, 68 = 0.8, NS; F4,62 = 0.7,
NS; F3,46 = 0.05, NS and F6,91 = 0.05, NS, respectively; Figure 7C–J).
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Figure 6. Effects of different antidepressants (10 mg/kg) on extracellular levels of DA, 5-HT and NA in the mPFC of
TAAR1-KO and WT mice. (A) Schematic depiction of experimental procedure. (B–D) Histograms show values of areas
under the curve (AUC [0 ..180], arbitrary units) for the response of venlafaxine (Ven), citalopram (Cit), bupropion (Bup),
selegiline (Sel) and reboxetine (Reb) upon DA (A), NA (B) and 5-HT (C). All data are means ± SEM. N = 6–8 per group.
p < 0.05, vehicle + antidepressant (#). VEH: vehicle.
2.8. Influence of O-PIT and Commonly Used Antidepressants on Marble-Burying Test in
TAAR1-KO Mice
In the marble-burying test, TAAR1-KO mice displayed a constitutive alteration in the
performance, with a total of 15.3 ± 1.2 buried marbles in WT mice and 18.4 ± 0.6 in TAAR1-
KO mice (F1, 29 = 6.0, p < 0.05; Figure 8A). A dose-dependent (2.5–40 mg/kg) suppression
of the number of buried marbles was provoked by o-PIT, but its effect was considerably
attenuated in TAAR1-KO mice. ANOVA indicated a significant GEN × DRUG interaction
(F4, 73 = 6.2, p < 0.01), effect of GEN (F1, 73 = 40.1, p < 0.01) and effect of DRUG (F4, 73 = 79.3,
p < 0.01). Even though there was no significant GEN × DRUG interaction for clomipramine
(F4, 51 = 0.9, NS; Figure 8C) and amitriptyline (F3, 66 = 2.3, NS; Figure 8D), TAAR1-KO
mice exhibit a slight rightward shift in the dose-response curve of tricyclic antidepres-
sants, which is similar to that one observed after o-PIT administration. Particularly, there
was a significant effect in both GEN and DRUG after the administration of clomipramine
(GEN effect: F1, 51 = 19.22, p < 0.01; DRUG effect: F4, 51 = 20.34, p < 0.01) and amitriptyline
(GEN effect: F1, 66 = 17.86, p < 0.01; DRUG effect: F3, 66 = 48.08, p < 0.01). TAAR1-KO mice
displayed similar reduction of the number of buried marbles to the WT mice after the
administration of duloxetine, venlafaxine, fluoxetine, citalopram, bupropion, radafax-
ine, selegiline and reboxetine (GEN × DRUG interaction: F3.44 = 1.5, NS; F3, 54 = 0.8, NS;
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F3, 43 = 0.5, NS; F3, 41 = 2.6, NS; F4, 47 = 0.7, NS; F4, 54 = 0.3, NS; F3, 47 = 1.5, NS and
F3, 51 = 0.6, NS, respectively; Figure 8E–L).
Figure 7. Influence of o-PIT on forced-swim test in TAAR1-KO and WT mice. (A) Schematic depiction of forced-
swim test. (B–J) Values correspond to the duration of immobility during 4 min test after acute o-PIT treatment
(2.5–40 mg/kg) (B), duloxetine (0.63–10 mg/kg) (C), venlafaxine (2.5–40 mg/kg) (D), maprotiline (0.63–40 mg/kg) (E),
fluoxetine (10–80 mg/kg) (F), bupropion (2.5–40 mg/kg) (G), radafaxine (2.5–40 mg/kg) (H), selegiline (2.5–40 mg/kg) (I)
and reboxetine (0.04–40 mg/kg) (J). Data represent means ± SEM. N = 8–12 per group. p < 0.05, influence of treatment (#) or
genotype (*). VEH: vehicle.
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Figure 8. Influence of o-PIT on marble-burying in TAAR1-KO and WT mice. (A) Schematic depiction of marble-burying
test. (B–L) Values correspond to the number of hidden marbles over 30 min after acute o-PIT treatment (2.5–40 mg/kg)
(B), clomipramine (2.5–20 mg/kg) (C), amitriptyline (0.63–5 mg/kg) (D), duloxetine (0.63–5 mg/kg) (E), venlafaxine
(2.5–20 mg/kg) (F), fluoxetine (2.5–10 mg/kg) (G), citalopram (0.63–10 mg7 kg) (H), bupropion (2.5–40 mg/kg) (I), radafaxine
(2.5–40 mg/kg) (J), selegiline (0.63–5 mg/kg) (K) and reboxetine (0.63–40 mg/kg) (L). Data represent means ± SEM.
N = 8–12 per group. p < 0.05, influence of treatment (#) or genotype (*). VEH: vehicle.
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2.9. Influence of O-PIT and Monoaminergic Receptor Antagonists on Marble-Burying Test in
TAAR1-KO Mice
High doses of o-PIT (>20 mg/kg) display robust anticompulsive effects in both WT
and TAAR1-KO mice. This indicates that, apart from TAAR1, o-PIT may act on addi-
tional receptor targets. D2 (Raclopride), α2 (RX821002), 5-HT1A (WAY100635), 5-HT2A
(MDL100907) and 5-HT2C (SB206553) antagonists were co-administered together with
o-PIT (Figure 9A). Even though there was a significant DRUG effect for all the performed
experiments (drug effect: F3, 38 = 54.96, p < 0.01; F3, 38 = 54.96, p < 0.01; F3, 47 = 16.15,
p < 0.01; F3, 45 = 34.62, p < 0.01; F3, 41 = 55.25, p < 0.01, respectively; Figure 9B–F), post hoc
test revealed that all the antagonists that were used failed to abolish the anticompulsive
effects of o-PIT in both WT and TAAR1-KO animals.
Figure 9. Influence of different monoaminergic receptors’ antagonists on o-PIT’s anticompulsive
effects in TAAR1-KO and WT mice. (A) Schematic depiction of the possible monoaminergic receptors
that may bind o-PIT. (B–F) Values correspond to the number of hidden marbles over 30 min after
pretreatment of raclopride (10 mg/kg) (B), RX821002 (0.65 mg/kg) (C), WAY100635 (0.63 mg/kg)
(D), MDL100907 (0.16 mg/kg) (E) or SB206553 (2.5 mg/kg) (F) and acute o-PIT treatment (20 mg/kg).
Data represent means ± SEM. N = 8–12 per group. p < 0.05, vehicle + vehicle vs. vehicle/antagonist
+ o-PIT (#), antagonist + vehicle vs. antagonist + o-PIT (§). VEH: vehicle.
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3. Discussion
3.1. Hypothermia Elicited by O-PIT Is Partially Mediated by TAAR1
One major effect of thyronamines is to counteract the hyperthermic effects of thyroid
hormones [35]. Consistent with an action in the brain, intracerebroventricular as well as
systemic injection of T1AM induces hypothermia [41]. The major brain centre that actively
modulates core temperature is the MPO [42]. This hypothalamic brain area harbours
warm-sensitive neurons, which act as the body’s thermostat [43]. Accordingly, direct
T1AM application in MPO decreases body temperature, indicating that the cooling effect
of thyronamines may stem from their activity on warm-sensitive neurons [44]. Supporting
this possibility, we demonstrate here a high density of TAAR1 expressing cells in MPO.
However, a previous study has reported that T1AM reduces body temperature in TAAR1-
KO mice [45]. Moreover, like thyronamines, direct application of clonidine, an α2 agonist, in
MPO causes hypothermia [46]. TAAR1 and α2-adrenoceptors share similar pharmacophore
space [21], and T1AM is also a ligand for α2-adrenergic receptor [36]. Hence, it was
suggested that T1AM-induced hypothermia is at least partially mediated by α2 expressing
neurons in MPO [47]. Here, we report that o-PIT induces hypothermia and that this
effect was blunted in TAAR1-KO mice supporting a role for TAAR1 in the mediation
of hypothermia. Interestingly, in light of the above remarks, the selective α2-antagonist,
RX821002, partially counteracted the hypothermic effect of o-PIT in both WT and TAAR1-
KO mice, indicating an additional role for α2 adrenergic receptors in the effect of o-PIT
on body temperature. Finally, since o-PIT caused some reduction of body temperature,
even in RX821002-treated TAAR1-KO mice, additional, currently unknown targets may
also mediate its hypothermic actions. Further work is warranted to further clarify the
mechanisms underlying the influence of o-PIT and TAAR1/trace amines, more generally,
upon core temperature, an important issue in view of their links to thyroid hormones [34,35].
3.2. O-PIT Enhancement of Prepulse Inhibition Is TAAR1-Dependent
O-PIT enhanced prepulse inhibition (PPI) in wildtype mice but not in TAAR1-KO
mice. Stimulation of striatal D2 signalling disrupts sensorimotor gating [48–50], and
schizophrenic patients display impairments in sensorimotor gating [51]. Hence, TAAR1’s
ability to diminish the activity of VTA dopamine neurons projecting to NAc may underlie
the action of o-PIT on PPI. These data provide further evidence that TAAR1 agonism
may be a novel antipsychotic approach. Additionally, the current study reveals a dense
positive population of TAAR1 in LEnt, which is crucial for performance of sensorimotor
gating tasks [52,53]. It has been described that T1AM–TAAR1 signalling in entorhinal
slices prevents ischemia-induced synaptic depression [54]. Thus, o-PIT may act on TAAR1
expressing cells in LEnt to increase prepulse inhibition.
3.3. O-PIT Increases TH Phosphorylation through TAAR1 in the Striatum
O-PIT significantly stimulated Ser19-TH phosphorylation in striatum. There was also
a trend for o-PIT to increase Ser40-TH. Ser19 phosphorylation of TH displays faster kinetics
than Ser40, which may explain the observed effects [55]. The stimulatory effects of o-PIT on
TH phosphorylation were abolished in TAAR1-KO mice. In agreement with these data,
T1AM stimulates TH phosphorylation through TAAR1-dependent Gs signalling [38]. In
this context, it is interesting to note that the endogenous TAAR1 agonist, tyramine, actually
inhibits TH phosphorylation in a TAAR1-independent manner [38]. It is established that
tyramine displays amphetamine-like properties and causes strong DA release [1,56–58],
which probably masks TAAR1-dependent actions on TH phosphorylation [38]. However,
thyronamines are TAAR1 agonists devoid of amphetamine-like properties and appear
suitable for studying TAAR1-dependent effects on DA system.
3.4. O-PIT Stimulates DA Release in mPFC through TAAR1
Dysfunction of PFC is strongly associated with mental illnesses such as MDD [59].
An increase in frontocortical DA transmission would be expected to have a beneficial
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impact upon both the affective and cognitive deficits in MDD [60,61]. Since TH is relatively
lowly expressed in PFC, we could not measure TH phosphorylation in this region. How-
ever, using in vivo microdialysis in freely moving animals, we found that o-PIT increases
DA release in mPFC in a manner that is dependent on TAAR1. Since TAAR1 is expressed
in raphe nuclei, it could be anticipated that o-PIT may promote 5-HT release and phospho-
rylation of tryptophan hydroxylase 2. However, the present study shows that o-PIT effects
upon monoamine release in mPFC are limited to the DAergic system.
3.5. A Differential Role of TAAR1 in the Antidepressant Actions of O-PIT vs. Clinically used
Classes of Antidepressants
Behavioural tests that are used to evaluate antidepressantDRUG efficacy include forced-
swim and marble-burying tests. Each test does not examine depression or compulsion,
per se, but rather pragmatic behavioural responses to clinically used agents for these
disorders. There is evidence that TAAR1 agonists exhibit antidepressant actions in animal
depression-like behavioural tests [23]. Likewise, the current study shows that o-PIT ex-
hibits antidepressant action, which is diminished, at least at lower doses, in TAAR1-KO
mice. A detailed pharmacological study was performed to better understand the action of
o-PIT in the marble-burying test. However, the effects of o-PIT in this test are not blocked
by antagonism of D2, α2, 5-HT1A, 5-HT2A or 5-HT2C receptors. Similar to o-PIT-induced
hypothermia, the exact class of receptor that are responsible for the effects of higher o-PIT
doses in this test requires further investigation. In contrast, the present data demonstrates
that the efficacy of commonly used monoamine-based antidepressants is not altered in
TAAR1-KO mice. Recently, we reported that the irreversible and nonselective MAO A/B in-
hibitor, tranylcypromine, display increased antidepressant efficacy in TAAR1-KO mice [16].
This may relate to tyramine build-up and general stimulation not seen with most antide-
pressants [16]. To fully understand the role of TAAR1 in mediating antidepressant actions,
additional behavioural tests will be important to perform in the future. Nevertheless,
corroborating the behavioural data, there was no influence of TAAR1 on the stimulatory
effects of the clinically used antidepressants on extracellular monoamine levels in mPFC
measured by microdialysis in freely moving animals.
4. Conclusions
This study demonstrates that o-PIT regulates, via TAAR1-dependent mechanisms,
core temperature, sensorimotor gating, striatal TH phosphorylation, mPFC DA release
and antidepressant behavioural responses. In contrast, the behavioural and neurochemical
actions of several classes of clinically used antidepressants do not involve TAAR1. These
data suggest that o-PIT is a useful experimental tool for studies of TAAR1-dependent
effects, particularly related to the DA system, and that o-PIT exerts antidepressant actions
in a manner distinct from monoamine-based antidepressant. It will be interesting in
future work to examine antidepressant actions of o-PIT in models that are resistant to
monoamine-based antidepressants.
5. Material and Methods
5.1. Animals
Homozygous TAAR1-KO mice lack the single intron-free Taar1 coding exon, which is
replaced with an IRES-LacZ reporter gene [18]. TAAR1-KO mice were backcrossed on a
pure C57BL/6J genetic background for 8 generations (Charles River). In all experiments,
5–8 weeks old male mice were used, and the experimenters were blinded as regard to the
genotype and treatment. They were housed 4–5 per cage under a 12 : 12 h light/dark cycle
and had free access to food and water. Housing and experimental procedures were fully
compliant with the principles of Care and Use of Laboratory Animals. All experiments
were conducted in accordance with European/EU (Directive 2010/63) directives on animal
experimentation.
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5.2. Drugs
o-phenyl-3-iodotyramine hydrochloride (o-PIT) was synthesized by Servier chemists.
Raclopride, RX821,002, WAY100,635, MDL100907 and SB206553 were purchased from
Sigma. Compounds were dissolved in sterile water. MDL100907 and SB206553 were
dissolved in sterile water plus lactic acid, and the pH was adjusted near neutrality. Sterile
water with or without lactic acid were used as vehicle control (VEH). All solutions were
injected in a volume of 10 mL/kg. Dose was expressed in terms of free base.
5.3. Plasma and Brain Levels of O-PIT
Blood samples (kept from coagulation with heparin) and whole brains (without cere-
bellum) were immediately taken sixty minutes after administration of o-PIT
(2.5–20 mg/kg, i.p.). Plasma (obtained from blood at 800 rpm) and homogenized brains
samples were assayed for o-PIT content using mass spectrometry. The detection limit was
5 ng/mL.
5.4. Histoenzymological Detection of β-Galactosidase
Frozen perfused (2% paraformaldehyde, 0.2% glutaraldehyde in PBS) brains were
cryostat cut in 30 µm coronal sections. The sections were washed 2 times for 5 min with
phosphate buffer solution (PBS). Then, they were incubated overnight in working buffer
solution prepared according to manufacturer instructions (GALS, Sigma–Aldrich). The
sections were washed 3 times for 5 min in PBS. They were mounted with aqueous media
and then digitalized with NanoZoomer (Hamamatsu, France).
5.5. Core Temperature Measurement
Experiments started at 10.00 a.m. and were randomized. Core temperature was
determined employing a rectal thermoprobe [62] and was measured in basal condition
and 30, 60 and 120 min after o-PIT administration. In interaction studies, RX821,002 was
administered 30 min before o-PIT (20 mg/kg; i.p.).
5.6. Acoustic Startle and Prepulse Inhibition
Startle reflexes were measured in mice as previously described [63]. Briefly, they were
detected in nonrestrictive Plexiglas cylinder (SR-LAB; San Diego Instruments, CA, USA).
Mice were familiarized with the startle procedure 1 week before testing. Startle stimuli
(110 dB, 50 msec), alone, or preceded by noise prepulses (20 msec) of 2, 4, 8 or 16 dB above
background (70 dB) were presented through a high-frequency speaker. Startle magnitudes
were immediately sampled for 65 msec (1 kHz). A startle response was defined as the peak
response of the 65 msec. Three consecutive blocks of test trials were as follows: blocks 1
and 3 consisted of 6 startle stimulus, alone trials; block 2 consisted of 12 startle stimulus,
alone trials; 10 startle prepulse trials per prepulse intensity and 10 no-stimulus trials.
5.7. Tyrosine Hydroxylase Phosphorylation in Brain Slices
Striatal slices of mouse brain (300 µm, Leica Vibratome) were preincubated in Krebs
buffer (118 mM NaCl, 4.7 mM KCl, 1.5 mM Mg2SO4, 1.2 mM KH2PO4, 25 mM NaHCO3,
11.7 mM glucose, 1.3 mM CaCl2) at 30 ◦C under constant oxygenation (95% O2/5% CO2)
for 60 min, with a change of buffer after 30 min. They were then treated with MDMA
for 5 min. The buffer was then removed, and the slices were rapidly frozen, sonicated
in 1% SDS and boiled for 10 min. Amounts of protein in homogenates were determined
using the bicinchoninic acid protein assay method (Pierce, Rockford, IL, USA). Equal
amounts of protein were processed by using 10% acrylamide gels. Western blot (WB) was
carried out with phosphorylation state-specific antibodies against P-Ser19-TH, P-Ser31-TH
and P-Ser40-TH (Millipore, Solna, Sweden) or antibodies that are not phosphorylation
state-specific against total TH and actin (Millipore). Antibody binding was detected by
enhanced chemiluminescence (ECL; GE Healthcare, Uppsala, Sweden) and quantified by
densitometry (NIH IMAGE 1.61 software). Data are percentage of total levels.
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5.8. Microdialysis in Freely Moving Mice
The microdialysis probe was surgically implanted in medial prefrontal cortex (mPFC)
as previously described [18]. The effect of o-PIT upon the different classes of neurotrans-
mitters was evaluated in separate experiments. (1) Monoamines were quantified using an
electrochemical procedure [18]. The limit of sensitivity was 0.2 pg. (2) Acetylcholine was
quantified in the absence of acetylcholinesterase inhibition [64]. The limit of sensitivity was
0.5 pg. (3) Amino acids were subjected to a precolumn derivatization using naphthalene
dicarboxaldehyde 5 mM and sodium cyanide (NaCN 10 mM, borate buffer 0.1 M, pH 9.5)
for 5 min at 21 ◦C. Fluorescent products of the reaction (5 µL) were injected. The mobile
phase was composed of ammonium acetate 50 mM, tetrahydrofuran–acetonitrile (gradient),
pH 6.8, and delivered at 0.35 mL/min. Amino acids were separated on a C18 column
(Hypersil, 250 × 2.1 mm, 5 µm) at 44 ◦C. A fluorimetric detector (Jasco FP2020+) settled at
λEx 420 nm and λEm 490 nm was used. The limit of sensitivity was 1.0 pg. The standard
trapezoidal method was used for the calculation of AUC (% × min × 10−3, arbitrary units).
In further experiments, the effects of diverse classes of clinically employed antidepressant
agent were examined.
5.9. Forced-Swim Test
As previously described [65], mice were placed in individual glass cylinders (24 cm
height; 12 cm diameter) containing 6 cm of water at 24 ± 0.5 ◦C for 6 min. Duration
of immobility was measured over the last 4 min. o-PIT was administered (s.c.) 30 min
prior testing.
5.10. Marble-Burying Behaviour
The procedure was described previously [65]. Mice were injected with o-PIT (s.c.) and
placed 30 min later in transparent polycarbonate cages (45 × 30 × 19 cm) containing a 5 cm
layer of sawdust and 24 glass marbles (1.5 cm diameter) evenly spaced against the wall of
the cage. The number of marbles buried at least two-thirds in the sawdust was recorded
30 min later. In interaction studies, raclopride, RX821,002, WAY100,635, MDL100907 and
SB206553 were administered 30 min before o-PIT (20 mg/kg; i.p.).
5.11. Statistical Analysis
Statistical comparisons of the effect of each DRUG in the two groups were achieved
using two-way ANOVA with genotype (GEN) and DRUG as between factors and was
followed by the Tukey, Sidak or Bonferroni post hoc tests for multiple comparisons. The
following three-way ANOVA were used: plus pretreatment (PRET) as between factor in
DRUG interaction studies; plus TIME as within factor and repeated measurement in kinetic
studies of the effect of o-PIT and plus INTENSITY as repeated within factor in PPI studies.
Values of p < 0.05 were considered significant.
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